Janux Therapeutics (JANX) Operating Leases (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Operating Leases of $19.1 million for Q1 2026, down 8.18% year-over-year from $20.8 million in Q1 2025, and down 3.28% quarter-over-quarter from $19.7 million in Q4 2025.
Janux Therapeutics (JANX) Operating Leases (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Operating Leases for 6 consecutive years, with $19.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 8.18% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (down 8.18% YoY), while the FY2025 annual figure was $19.7 million, down 7.19% from the prior year.
- Operating Leases eased to $19.1 million in Q1 2026 per JANX's latest filing, from $19.7 million in the prior quarter.
- Across five years, Operating Leases topped out at $24.5 million in Q4 2022 and bottomed at $19.1 million in Q1 2026.
- Historically, Operating Leases has averaged $22.2 million across 5 years, with a median of $22.4 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases soared 104647.83% — and 2025, when it decreased 8.44%.
- Janux Therapeutics' Operating Leases stood at $24.5 million in 2022, then declined by 6.18% to $23.0 million in 2023, then declined by 7.6% to $21.3 million in 2024, then dropped by 7.19% to $19.7 million in 2025, then decreased by 3.28% to $19.1 million in 2026.
- Business Quant data shows JANX's Operating Leases at $19.1 million in Q1 2026, $19.7 million in Q4 2025, and $20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.44 Mn |
| Mar 31, 2026 | 19.10 Mn |
| Dec 31, 2025 | 19.75 Mn |
| Sep 30, 2025 | 20.38 Mn |
| Jun 30, 2025 | 20.32 Mn |
| Mar 31, 2025 | 20.80 Mn |
| Dec 31, 2024 | 21.28 Mn |
| Sep 30, 2024 | 21.74 Mn |
| Jun 30, 2024 | 22.19 Mn |
| Mar 31, 2024 | 22.61 Mn |
| Dec 31, 2023 | 23.03 Mn |
| Sep 30, 2023 | 23.43 Mn |
| Jun 30, 2023 | 23.82 Mn |
| Mar 31, 2023 | 24.18 Mn |
| Dec 31, 2022 | 24.54 Mn |
| Sep 30, 2022 | 24.09 Mn |
| Jun 30, 2022 | 23.27 Mn |
| Sep 30, 2021 | 23,000.00 |